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The standard medical treatment for HAC (PDH and ATH) dogs has long been mitotane. Mitotane leads 
to selective necrosis of the adrenal cortex, which may be partially or completely destroyed, depending 
on the treatment protocol. The efficacy of mitotane is favourable and more than 80% of dogs with PDH 
have a good to excellent response. Disadvantages of mitotane include potential development of 
adrenocortical insufficiency, possible drug intolerance, and a relatively high frequency of relapses 
during therapy. The first report of the use of trilostane was by Hurley et al in 1998, who successfully 
treated 13 dogs with PDH and 2 with ATH. Since then, the drug has gained wide popularity and is now 
licensed for the use in dogs under the name of Vetoryl. Various clinical trials have shown that 
trilostane is an efficacious drug and that the majority of dogs with HAC show good clinical response.  If 
used cautiously (e.g. low starting dose and close monitoring), side effects are rare. However, many 
questions on the exact mode of action, optimal dose regimen and monitoring protocol are still 
unanswered. It is also not known, why some dogs show poor clinical response despite tight control of 
the adrenal function and why dose requirements vary tremendously.  
From studies in humans and various other species it is known that trilostane is a competitive inhibitor of 
3β-hydroxysteroid-dehydrogenase. This enzyme system mediates the conversion of pregnenolone to 
progesterone in the adrenal gland. Cortisol, aldosterone and androstendione are produced from 
progesterone via various biochemical pathways. Since trilostane inhibits progesterone synthesis, it 
blocks the synthesis of its end products. Recently, it was shown that also in dogs, trilostane has an 
inhibitory effect on the 3β-hydroxysteroid dehydrogenase enzyme system. Surprisingly, studies 
revealed additional effects more distal in the enzyme cascade, most likely on the 11β-hydroxylase and 
possibly on the 11β-hydroxysteroid dehydrogenase.  It has also been shown that trilostane influences 
the interconversion of active cortisol to inactive cortisone, either directly or indirectly, leading to a 
reduced cortisol to cortisone ratio. Trilostane may also have an effect on the intracellular glucocorticoid 
receptors; in rats it was shown that glucocorticoid mRANA were significantly decreased by trilostane. 
After absorption, trilostane has to be converted to active metabolites, such as ketotrilostane in the liver, 
a process which has not been thoroughly studied in dogs.  The multitude of effects, which may not be 
equally active in all dogs, most likely is one of the reasons for the variable clinical response in dogs 
treated with trilostane.  
Another potential reason is the variability in plasma levels of trilostane which may be due to low water 
solubility and inconsistent absorption. Feeding increases the absorption of the drug. Peak plasma 
concentrations of trilostane are generally seen after 1.5 – 2 hours and return to baseline levels is after 
10 – 18 hours. Consequently, results of the ACTH stimulation test vary considerably depending on the 
time of testing after drug administration. A recent study demonstrated that post-ACTH cortisol levels 
were significantly higher when the ACTH test was started 4 hours after administration of trilostane 
compared to a start after 2 hours.  
Trilostane not only lowers the cortisol concentration, but also the aldosterone concentration. The 
decrease of aldosterone, however, is considerably less than that of cortisol.  Although some dogs with 
HAC show mild hyperkalemia, there is no correlation between potassium and aldosterone 
concentrations.  
Adverse effects are seen in 10 – 25% of dogs and are often mild (e.g. GI signs) and self-limiting. In 
some dogs, however, hypoadrenocorticism may develop requiring withdrawal of the drug and possibly 
symptomatic treatment (IV fluids, glucocorticoids). Hypoadrenocorticism may be short-lived and due to 
an overdose of trilostane. It may, however, also be caused by adrenal necrosis leading to long-lasting 
or permanent adrenal insufficiency and even to death. One of our recent studies suggests, that adrenal 
necrosis is not due to a direct effect of trilostane, but is caused by the increase of endogenous ACTH. 
Synthesis of endogenous ACTH increases substantially during treatment with trilostane due to the lack 
of negative feedback.   In our hospital, adrenal necrosis has become a very rare event since we use low 
dosages based on kg body weight.  
Over the years, treatment protocols have changed considerably and there are currently no widely 
accepted guidelines. 
During the initial years, trilostane dose was based on the available capsule size of 30 mg and 3 
categories of bodyweight: 30 mg (1/2 capsule) SID for dogs < 5 kg, 60 mg SID for dogs 5-20 kg, and 
120 mg SID for dogs > 20 kg. Today 10mg, 30 mg, 60 mg and 120 mg capsules are commercially 
available.  Re-formulation by a pharmacist may provide additional sizes (e.g. 5 mg, 2.5 mg). In 2006, 
endocrinologists of seven European countries suggested in a consensus statement that initial dose 
should be according to bodyweight and should be in the range of 2 – 5 mg/kg (in dogs < 10 kg at the 
lower end of the dose range). Applications should be SID, in the morning with food. Re-evaluations 
should be performed after 1-2 weeks, 4 weeks, 12 weeks and then every 3 months including history, 
physical examination, the most important blood parameters (kidney parameters, liver enzymes, 
electrolytes) and an ACTH stimulation test. The latter test should be performed 2 to 3 hours after 
trilostane administration, which corresponds to its peak effect. The target range of the post ACTH 
cortisol level at 2-3 hours post pill should be 40 to 150 nmol/l (1.4 – 5.4 µg/dl). Adjustments of trilostane 
dose should be made in increments of 10 to 30 mg/dog. Some time after those recommendations, it 
was in fact shown that dosing per kg body weight is associated with less side effects compared to 
dosing according to weight categories. Recently, it became obvious, that even lower doses are 
efficacious to control the disease. Various authors have recently suggested using BID instead of SID 
administration. BID administration may lead to a slightly faster control of the disease and possibly 
increases the number of dogs with good clinical response. However, the need of BID administration 
may have a negative impact on owner compliance. In our hospital, we amended the protocol various 
times during the last 15 years. The main changes were reductions of initial trilostane doses. We 
currently start trilostane therapy with a dose of 1 (- 1.5) mg/kg SID and ask the owner to administer the 
drug in the morning with the same type and amount of food. In large dogs (> 20 kg), usually less than 1 
mg/kg SID is given (e.g. a 30 kg dog receives 20 mg, a 40 kg dog 30 mg SID). Re-evaluations are 
scheduled after 2, 4, 8, 12 - 16 weeks and every 4 - 6 months thereafter. Besides clinical signs, the 
post-ACTH cortisol concentration is used to amend the dose. The ACTH test is performed 2 – 3 hours 
after trilostane administration and our post-ACTH cortisol target is 54 – 135 nmol/l (2 – 5 µg/dl). After 8 
– 12 weeks we evaluate, if SID application is adequate by performing an ACTH test 24 hours after the 
last trilostane administration.  If post-ACTH cortisol concentrations are above approximately 200 nmol/l 
(7.5 µg/dl), application frequency is switched to BID. In dogs with diabetes mellitus and HAC, trilostane 
is administered BID from the beginning. The majority of dogs is well controlled with SID application, 
some dogs, however, benefit from a switch to BID therapy.  
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